

Grioni Matteo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7147708/publications.pdf>

Version: 2024-02-01

26
papers

1,697
citations

361413

20
h-index

642732

23
g-index

26
all docs

26
docs citations

26
times ranked

3043
citing authors

#	ARTICLE	IF	CITATIONS
1	Commensal bacteria promote endocrine resistance in prostate cancer through androgen biosynthesis. <i>Science</i> , 2021, 374, 216-224.	12.6	135
2	Much More Than IL-17A: Cytokines of the IL-17 Family Between Microbiota and Cancer. <i>Frontiers in Immunology</i> , 2020, 11, 565470.	4.8	63
3	CD4+ T Cells Sustain Aggressive Chronic Lymphocytic Leukemia through a CD40L-Independent Mechanism. <i>Blood</i> , 2019, 134, 683-683.	1.4	0
4	Targeting Tumor Vasculature with TNF Leads Effector T Cells to the Tumor and Enhances Therapeutic Efficacy of Immune Checkpoint Blockers in Combination with Adoptive Cell Therapy. <i>Clinical Cancer Research</i> , 2018, 24, 2171-2181.	7.0	40
5	Bimodal CD40/Fas-Dependent Crosstalk between iNKT Cells and Tumor-Associated Macrophages Impairs Prostate Cancer Progression. <i>Cell Reports</i> , 2018, 22, 3006-3020.	6.4	62
6	Microbiota-driven interleukin-17-producing cells and eosinophils synergize to accelerate multiple myeloma progression. <i>Nature Communications</i> , 2018, 9, 4832.	12.8	144
7	T Cells Redirected to a Minor Histocompatibility Antigen Instruct Intratumoral TNF \pm Expression and Empower Adoptive Cell Therapy for Solid Tumors. <i>Cancer Research</i> , 2017, 77, 658-671.	0.9	30
8	Modifications of the mouse bone marrow microenvironment favor angiogenesis and correlate with disease progression from asymptomatic to symptomatic multiple myeloma. <i>Oncolmmunology</i> , 2015, 4, e1008850.	4.6	27
9	Tenascin-C Protects Cancer Stem \hat{e} like Cells from Immune Surveillance by Arresting T-cell Activation. <i>Cancer Research</i> , 2015, 75, 2095-2108.	0.9	112
10	Angiogenesis Associated with Alterations of the Bone Marrow Microenvironment Predicts Multiple Myeloma Progression to Symptomatic Disease in Mice and Humans. <i>Blood</i> , 2014, 124, 5678-5678.	1.4	0
11	Booster Vaccinations against Cancer Are Critical in Prophylactic but Detrimental in Therapeutic Settings. <i>Cancer Research</i> , 2013, 73, 3545-3554.	0.9	17
12	Gene Signatures Distinguish Stage-Specific Prostate Cancer Stem Cells Isolated From Transgenic Adenocarcinoma of the Mouse Prostate Lesions and Predict the Malignancy of Human Tumors. <i>Stem Cells Translational Medicine</i> , 2013, 2, 678-689.	3.3	20
13	Boosting anticancer vaccines. <i>Oncolmmunology</i> , 2013, 2, e25032.	4.6	6
14	Prostate cancer stem cells are targets of both innate and adaptive immunity and elicit tumor-specific immune responses. <i>Oncolmmunology</i> , 2013, 2, e24520.	4.6	38
15	Abstract A83: Modifications of the bone marrow microenvironment in the transition from monoclonal gammopathy of undetermined significance to multiple myeloma in V κ *MYC mice.. , 2013, , .		0
16	Modulation of Microenvironment Acidity Reverses Energy in Human and Murine Tumor-Infiltrating T Lymphocytes. <i>Cancer Research</i> , 2012, 72, 2746-2756.	0.9	470
17	Targeting TNF- \hat{a} to Neoangiogenic Vessels Enhances Lymphocyte Infiltration in Tumors and Increases the Therapeutic Potential of Immunotherapy. <i>Journal of Immunology</i> , 2012, 188, 2687-2694.	0.8	128
18	Modulators of Arginine Metabolism Do Not Impact on Peripheral T-Cell Tolerance and Disease Progression in a Model of Spontaneous Prostate Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 1012-1023.	7.0	29

#	ARTICLE	IF	CITATIONS
19	iNKT Cells Control Mouse Spontaneous Carcinoma Independently of Tumor-Specific Cytotoxic T Cells. PLoS ONE, 2010, 5, e8646.	2.5	61
20	Concomitant Tumor and Minor Histocompatibility Antigen-Specific Immunity Initiate Rejection and Maintain Remission from Established Spontaneous Solid Tumors. Cancer Research, 2010, 70, 3505-3514.	0.9	25
21	Modulators of arginine metabolism support cancer immunosurveillance. BMC Immunology, 2009, 10, 1.	2.2	79
22	Vasculature-targeted tumor necrosis factor- α increases the therapeutic index of doxorubicin against prostate cancer. Prostate, 2008, 68, 1105-1115.	2.3	47
23	Peripheral T-Cell Tolerance Associated with Prostate Cancer Is Independent from CD4+CD25+ Regulatory T Cells. Cancer Research, 2008, 68, 292-300.	0.9	59
24	Prolonged exposure of dendritic cells to maturation stimuli favors the induction of type-2 cytotoxic T α , lymphocytes. European Journal of Immunology, 2006, 36, 3157-3166.	2.9	6
25	Type 2 Cytotoxic T Lymphocytes Modulate the Activity of Dendritic Cells Toward Type 2 Immune Responses. Journal of Immunology, 2006, 177, 2131-2137.	0.8	21
26	Peripheral T α cell tolerance occurs early during spontaneous prostate cancer development and can be rescued by dendritic cell immunization. European Journal of Immunology, 2005, 35, 66-75.	2.9	78